CD274 and non-small cell lung carcinoma: Combined with the PD-1 inhibitor simiprimab in PD-L1-positive advanced NSCLC patients (who had previously received ≤2 lines of therapy), ORR was 10%, DCR was 80%, and median PFS was 5.5 months (NCT05142189) (28).